More recently, treatment of type 2 diabetes with rosiglitazone has been reported to cause decreases in μ-calpain activity, the restoration of platelet PECAM-1 levels and diminished platelet responsiveness to thrombin [37]. The gene discussed is PECAM1; the disease is type 2 diabetes mellitus.